Ascendis Pharma ADR Logo
US04351P1012

Ascendis Pharma ADR

Ins Portfolio

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt 175,52 ( 50,02 %). Der Median liegt bei 180,86 ( 54,58 %).

Kaufen
  10
Halten
  1
Verkaufen
  0

Scoring-Modelle

Dividenden-Strategie 0 / 15
HGI-Strategie 9 / 18
Levermann-Strategie -7 / 13
Powered by aktien.guide

News

  • Foto von Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency
    30.09. - 12:30 Uhr

    Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

    COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD). » Mehr auf globenewswire.com

  • Foto von New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
    30.09. - 12:30 Uhr

    New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024

    COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon™ PTH (palopegteriparatide; marketed as YORVIPATH®) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population.1,2,3,4 In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency. » Mehr auf globenewswire.com

  • Foto von Ascendant Resources Approved for EU Sponsored Cutting-Edge Geophysical "Undercover" Program at Its Lagoa Salgada Project
    30.09. - 10:00 Uhr

    Ascendant Resources Approved for EU Sponsored Cutting-Edge Geophysical "Undercover" Program at Its Lagoa Salgada Project

    Lagoa Salgada selected to participate in the European Union's UNDERCOVER Project to unlock hidden critical mineral deposits at depth using cutting edge Geophysical techniques UNDERCOVER Project will employ Seismic Reflection and Refraction, Magnetotellurics (MT), Gravity and Magnetic Surveys, Electromagnetic (EM) Surveys, and Joint Inversion Techniques to delineate potential deposits of critical minerals at depth The two-year program is fully funded by the EU under its Horizon Program and is expected to commence in Q1 2025 TORONTO, ON / ACCESSWIRE / September 30, 2024 / Ascendant Resources Inc. (TSX:ASND), through its Portuguese subsidiary, Redcorp Empreendimentos Mineiros Lda is pleased to announce its award of EU funding through its participation in the UNDERCOVER project. The project aims to advance mineral exploration by applying state-of-the-art geophysical technologies to uncover hidden mineral deposits at significant depths. » Mehr auf accesswire.com

Unternehmenszahlen

Im letzten Quartal hatte Ascendis Pharma ADR einen Umsatz von 36,18 Mio und ein Nettoeinkommen von 109,93 Mio
(EUR) Juni 2024
YOY
Umsatz 36,18 Mio 23,66%
Bruttoeinkommen 22,67 Mio 34,23%
Nettoeinkommen 109,93 Mio 9,47%
EBITDA 129,52 Mio 20,06%

Fundamentaldaten

Metrik Wert
Marktkapitalisierung
6,70 Mrd
Anzahl Aktien
57,35 Mio
52 Wochen-Hoch/Tief
148,56 - 78,70
Dividenden Nein
Beta
0,64
KGV (PE Ratio)
13,67
KGWV (PEG Ratio)
5,05
KBV (PB Ratio)
20,85
KUV (PS Ratio)
21,08

Unternehmensprofil

Ascendis Pharma A/S, ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entwicklung von Therapeutika für ungedeckte medizinische Bedürfnisse. Das Unternehmen bietet SKYTROFA für die Behandlung von Patienten mit Wachstumshormonmangel (GHD) an. Außerdem entwickelt es TransCon Growth Hormone (hGH) für pädiatrische GHD in Japan, TransCon hGH für Erwachsene mit GHD, TransCon Parathyroid Hormon für Hypoparathyreoidismus bei Erwachsenen und TransCon CNP für pädiatrische Achondroplasie. Darüber hinaus entwickelt das Unternehmen TransCon Toll Like Receptors 7/8 Agonist für die intratumorale Verabreichung und TransCon IL-2 ß/g für die systemische Verabreichung. Das Unternehmen wurde im Jahr 2006 gegründet und hat seinen Hauptsitz in Hellerup, Dänemark.

Name
Ascendis Pharma ADR
CEO
Jan Moller Mikkelsen
Sitz Hellerup,
Dänemark
Website
Industrie
Chemikalien
Börsengang
28.01.2015
Mitarbeiter 879

Ticker Symbole

Börse Symbol
NASDAQ
ASND
Frankfurt
A71.F
Düsseldorf
A71.DU
München
A71.MU
🍪

Parqet nutzt Cookies. Erfahre Mehr